Document Detail

2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine.
MedLine Citation:
PMID:  7514439     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Fludarabine monophosphate and 2Chlorodeoxyadenosine are nucleoside analogues with activity against Waldenström macroglobulinemia. However, it is not clear whether prior exposure to one analogue precludes response to the other compound.
PATIENTS AND METHODS: Fourteen patients with Waldenström's macroglobulinemia and prior exposure to fludarabine were treated with two courses of 2chlorodeoxyadenosine.
RESULTS: Three out of four patients that had previously responded to fludarabine and were relapsing from unmaintained remission, achieved a partial response with 2chlorodeoxyadenosine therapy. However, only one out of 10 patients with disease resistant to fludarabine responded to 2chlorodeoxyadenosine.
CONCLUSIONS: 2chlorodeoxyadenosine may be effective in patients with Waldenström macroglobulinemia sensitive to fludarabine. However, this compound has limited activity for patients with disease resistant to fludarabine.
M A Dimopoulos; D M Weber; H Kantarjian; M Keating; R Alexanian
Related Documents :
16914909 - Clonal karyotype evolution involving ring chromosome 1 with myelodysplastic syndrome su...
282809 - Leukemia in radiation-treated patients: cytogenetic studies in eight cases.
14965169 - Hairy cell leukemia: an autopsy study.
12814399 - Numbers of colony-forming progenitors in patients with systemic mastocytosis: potential...
20040759 - Acute erythroid leukemia: a reassessment using criteria refined in the 2008 who classif...
11920509 - Prognostic significance of tie-1 protein expression in patients with early chronic phas...
21983349 - The presence of -308a tnfa is associated with anemia and thrombocytopenia in patients w...
2026239 - Quality assessment and predictors of survival in long-term domiciliary oxygen therapy. ...
19355849 - Long-term follow-up of patients immunized with an1792: reduced functional decline in an...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  5     ISSN:  0923-7534     ISO Abbreviation:  Ann. Oncol.     Publication Date:  1994 Mar 
Date Detail:
Created Date:  1994-06-23     Completed Date:  1994-06-23     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  288-9     Citation Subset:  IM    
Department of Hematology, University of Texas, M.D. Anderson Cancer Center Houston.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimetabolites, Antineoplastic / therapeutic use*
Cladribine / adverse effects,  therapeutic use*
Drug Resistance
Middle Aged
Treatment Outcome
Vidarabine Phosphate / analogs & derivatives*,  therapeutic use
Waldenstrom Macroglobulinemia / drug therapy*
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 1X9VK9O1SC/fludarabine phosphate; 29984-33-6/Vidarabine Phosphate; 4291-63-8/Cladribine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor recepto...
Next Document:  Immunofluorescence analysis of B-1 cell ontogeny in the mouse.